| abstract |
The compounds of the formula (1) are muscarinic receptor antagonists. Pharmaceutical compositions containing said compounds, processes and intermediates for preparing said compounds and methods for using said compounds to treat lung conditions. Claim 1: A compound, characterized in that the compound is a pharmaceutically acceptable salt selected from a salt of acetic, ascorbic, benzenesulfonic, benzoic, canphosulfonic, citric, ethanesulfinic, edisyl, fumaric, gentisic, gluconic, glucoronic, glutamic, hippuric, hydrobromic acid. , hydrochloric, isethionic, lactic, lactobionic, maleic, malic, mandelic, methanesulfonic, mucic, naphthalenesulfonic, naphthalen-1,5-disulfonic, naphthalen-2,6-disulfonic, nicotinic, nitric, orotic, pamoic, pantothenic, phosphoric, succinic , sulfuric, tartaric, p-toluenesulfonic and xinafoic 1- (2 - {[4- (4-carbamoylpiperidin-1-ylmethyl) benzoyl] methylamino} ethyl) piperidine-4-yl ester of biphenyl-2-ylcarbamic acid of formula ( 2). |